ConductScience.org, home

Paper41599016

Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins.

Gonepudi NK and 4 others. Pathogens, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins. Papers, record 41599016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41599016

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Structure-Guided Design of Peptide Inhibitors Targeting Class I Viral Fusion Proteins.
PubMed
Journal
Pathogens
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-09-26
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gonepudi NKNarendra Kumarhttps://orcid.org/0009-0005-3327-0116
2Baffour Awuah HHarry
3Xu WWanghttps://orcid.org/0000-0003-4452-9240
4Katte RHRevansiddha Hhttps://orcid.org/0000-0002-3844-8797
5Lu MMaolin

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Viral Fusion ProteinsMajor topic
PeptidesMajor topic
Antiviral AgentsMajor topic
Viral Fusion Protein InhibitorsMajor topic
Drug DesignMajor topic
Humans
Virus Internalization

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AI181600NIAID NIH HHSUnited StatesR01AI181600PubMed and NIHNIH RePORTER
R35 GM151169NIGMS NIH HHSUnited StatesR35GM151169PubMed and NIHNIH RePORTER
R35GM151169NIGMS NIH HHSUnited StatesR35GM151169PubMed and NIHNIH RePORTER
R01AI181600National Institute of Allergy and Infectious DiseasesR01AI181600PubMed and NIHNIH RePORTER

Download CSV of grants

References191

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133068234Influenza Hemagglutinin Head Domain Mimicry by Rational Design.Protein J2020https://conductscience.org/library/papers/33068234PubMed
232805734Structures and distributions of SARS-CoV-2 spike proteins on intact virions.Nature2020https://conductscience.org/library/papers/32805734PubMed
324067982Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus.J Virol2013https://conductscience.org/library/papers/24067982PubMed
432075877Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.Science2020https://conductscience.org/library/papers/32075877PubMed
521613394Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.J Virol2011https://conductscience.org/library/papers/21613394PubMed
623565220Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action.PLoS One2013https://conductscience.org/library/papers/23565220PubMed
732376627Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.J Virol2020https://conductscience.org/library/papers/32376627PubMed
812600315Membrane fusion.Cell2003https://conductscience.org/library/papers/12600315PubMed
923804636
A cholesterol tag at the N terminus of the relatively broad-spectrum fusion inhibitory peptide targets an earlier stage of fusion glycoprotein activation and increases the peptide's antiviral potency in vivo.
J Virol2013https://conductscience.org/library/papers/23804636PubMed
1028423338An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses.Immunity2017https://conductscience.org/library/papers/28423338PubMed
1139070180Development of potent pan-coronavirus fusion inhibitors with a new design strategy.MedComm (2020)2024https://conductscience.org/library/papers/39070180PubMed
1215150417Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15150417PubMed
1324743141Repurposing staples for viruses: applying peptide design to RSV prophylaxis.J Clin Invest2014https://conductscience.org/library/papers/24743141PubMed
1424473083Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.Nat Commun2014https://conductscience.org/library/papers/24473083PubMed
1512615056Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion.Biochem Biophys Res Commun2003https://conductscience.org/library/papers/12615056PubMed
168312047A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.AIDS Res Hum Retroviruses1993https://conductscience.org/library/papers/8312047PubMed
1733914735Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.PLoS Biol2021https://conductscience.org/library/papers/33914735PubMed
1839640534HIV-1-envelope trimer transitions from prefusion-closed to CD4-bound-open conformations through an occluded-intermediate state.Comput Struct Biotechnol J2024https://conductscience.org/library/papers/39640534PubMed
1937039514Rapid Evaluation of Staple Placement in Stabilized α Helices Using Bacterial Surface Display.ACS Chem Biol2023https://conductscience.org/library/papers/37039514PubMed
2031262533Molecular Mechanism of HIV-1 Entry.Trends Microbiol2019https://conductscience.org/library/papers/31262533PubMed

See all 191 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42466597Identification of Two Competition-Defined Neutralizing Antibody Groups Targeting the HHV-6B gH/gL/gQ1/gQ2 Complex Independent of CD134 Binding.Microbiol Immunol2026https://conductscience.org/library/papers/42466597PubMed
42357691Membrane-Anchored and Sequence-Oriented Antiviral Activity of Fusion-Inhibitory Lipopeptides Derived from the SARS-CoV-2 Spike Glycoprotein S2 Subunit.Viruses2026https://conductscience.org/library/papers/42357691PubMed
42082899Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain.Microbiologyopen2026https://conductscience.org/library/papers/42082899PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41599016

GET https://conductscience.org/api/papers/v1/41599016/references?page=2